Cannabis Law Report

DECEMBER 9, 2021

The Financing will allow the Company to continue progressing its R&D, clinical trials and technology initiatives. “I I’m proud of our accomplishments to date and look forward to kicking off multiple clinical trials in early 2022,” said CEO, Josh Bartch. DENVER, Dec.

Clinical Trials 52

Clinical Trials Research and Development Treatment Therapy 52

The Cannigma

MAY 19, 2021

This was notoriously reflected in the 2020 arrest of a Japanese man and woman for speaking positively about using cannabis in social media posts. In 2019, Japan approved clinical trials for Epidiolox — a cannabis derived medicine used to treat severe forms of childhood epilepsy such as Dravet and Lennox-Gastaut syndromes.

Law 145

Law Legalization Clinical Trials CBD 145

Puff Puff Post

MARCH 10, 2020

“We are very pleased with the rapid completion of enrollment achieved by the team at the Centre for Human Drug Research (CHDR) in Leiden, the Netherlands,” said Alexandra Mancini, InMed’s Senior Vice President of Clinical Development & Regulatory Affairs. SOURCE InMed Pharmaceuticals Inc.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

Cannabis Law Report

AUGUST 12, 2021

loss per share, during the same period in 2020 (after including non-cash share-based compensation expense of $11.4 Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. million during the same period in 2020. million, or $0.79

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

Project CBD

FEBRUARY 28, 2023

This was somewhat less than the nearly 37% decline seen in 2020. decline from 2020. 13 Although many review authors reported inconclusive findings due to low-quality studies, they noted that evidence from human clinical trials seems to support CBD’s positive effects on nociceptive pain (i.e., million on these products.

CBD 143

CBD Seed-To-Sale Food Access 143

Cannabis Law Report

AUGUST 25, 2021

“Lucid has successfully developed a strong pipeline of novel therapeutic compounds — supported by IP in order to advance to future clinical trials — and we are confident that the experience the Lucid leadership team brings will allow us to immediately start the process towards clinical trials to further advance these promising therapies.

Clinical Trials 85

Clinical Trials Research and Development Therapy Conditions 85

Cannabis Law Report

JANUARY 27, 2022

The distribution of clinical trials across Phase I-IV indicates that the majority of trials for FXS have been in the early and midphases of development, with 77% of trials in Phase I-II, and only 23% in Phase III-IV. The US has a substantial lead in the number of FXS clinical trials globally. Premutation.

Clinical Trials 40

Clinical Trials Therapy Cannabinoids Topical 40

Cannabis Law Report

JANUARY 13, 2020

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. Key Priorities for 2020.

Pharmaceutical 51

Pharmaceutical Clinical Trials Research and Development Programs 51

Cannabis Law Report

AUGUST 3, 2021

FDA) or equivalent foreign regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final approval from the U.S. Food and Drug Administration (U.S. FDA or equivalent foreign regulatory agencies, the unknown outcome of any applications or requests to U.S.

Clinical Trials 81

Clinical Trials Therapy Collective Research and Development 81

Cannabis Law Report

SEPTEMBER 2, 2021

FDA) or equivalent foreign regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final approval from the U.S. Food and Drug Administration (U.S. FDA or equivalent foreign regulatory agencies, the unknown outcome of any applications or requests to U.S.

Clinical Trials 76

Clinical Trials Research and Development Therapy Collective 76

Cannabis Law Report

NOVEMBER 12, 2021

Completed manufacturing of ANEB-001 capsules for upcoming Phase 2 clinical trial. On track to commence Phase 2 proof-of-concept clinical trial with ANEB-001 for the treatment of acute cannabinoid intoxication by year-end. The founding co-chairs are Andrew Monte, M.D., and Arjun Chanmugam, M.D., 19,892,636. . . .

Pharmaceutical 52

Pharmaceutical Clinical Trials Business Research and Development 52

Cannabis Law Report

OCTOBER 15, 2021

RespRx, in addition to its clinical research with COPD, has been engaged in select, non-clinical trials to treat cancer and demonstrated effectiveness. The 2020 CBD Nutraceuticals Market had an estimated value of $5.2 In conjunction with PAOG’s ongoing IND initiative for RespRx, and PAOG’s connection with U.S.

Treatment 52

Treatment Research and Development CBD eCommerce 52

Cannabis Law Report

MAY 29, 2022

The company has been building its two adjacent 10,000 square foot facilities since August 2020. The grand opening event and reception invited investors, stakeholders and the residents of Princeton to take a tour through the facilities. The psilocybin mushrooms are headed to clinical trials, drug companies and medical facilities. “I’m

Research and Development 52

Research and Development Clinical Trials Medicine Access 52

Cannabis Law Report

MARCH 29, 2020

At an HIV Community Cannabis Education event held in Toronto, a cannabis company proudly declared their company had not had a single product recall to date. This post explores the manufacturing and research standards to consider when conducting research studies with cannabis. . . Product Quality in Manufacturing.

Compliance 69

Compliance Compliance Supply Chain Research and Development 69

Cannabis Law Report

APRIL 8, 2022

This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. For over three decades, we’ve been working to achieve mass mental health throughout the United States, Canada, and Europe.

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Cannabis Law Report

NOVEMBER 24, 2019

Upcoming Events. Dr. Griffiths and Dr. Johnson will be speaking at Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks conference in Washington DC. Dr. Griffiths will be providing background on psilocybin, and Dr. February 18, 2020. February 28, 2020.

Therapy 59

Therapy Treatment Medicine Clinical Trials 59

Cannabis Law Report

NOVEMBER 26, 2021

Can-Fite Ends Phase II COVID-19 Trial to Focus on Core Indications – In 2020, with the aim of developing a much-needed drug to treat manifestations of COVID-19, mainly the Cytokine Release Syndrome, Can-Fite initiated a Phase II COVID-19 study of its lead drug candidate, Piclidenoson, with patient enrollment in Israel and Europe.

Clinical Trials 40

Clinical Trials Research and Development Treatment Data 40

Cannabis Law Report

JUNE 7, 2021

Department of Agriculture (USDA) or equivalent foreign regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final or conditional approval from the U.S. Food and Drug Administration (U.S. For Applied DNA: Investor contact: Sanjay M.

Clinical Trials 49

Clinical Trials Research and Development Therapy Supply Chain 49

Cannabis Law Report

NOVEMBER 9, 2021

As an institution dedicated to diagnosing and treating serious blood diseases and with the ability to pursue investigational medicines from development to manufacture and clinical trial for patients who have exhausted all approved treatment options, having a cost-effective and rapid production chain is integral to ÚHKT’s mission.

Clinical Trials 40

Clinical Trials Research and Development Therapy Supply Chain 40

Cannabis Law Report

DECEMBER 7, 2021

The search included studies through 11-May-2020. While cannabidiol was associated with a reduction in reported seizure events (RR?=?0.59, A qualitative assessment suggests that medical cannabinoids might be associated with adverse mental events. 1.69, 95% CI [1.20–2.36]) 1), 95%CI [??1.39–(??0.60)]) 0.59, 95% CI [0.36–0.97]),

Safety 52

Safety Cannabinoids Data Events 52

Healer

DECEMBER 17, 2021

Drug interactions reported in the scientific literature most often occur at very high doses used in clinical trials of epilepsy and other conditions. Adverse events reported for these participants were mild and included fatigue, diarrhea, and nausea. . The Journal of Clinical Pharmacology 60.4 2020): 432-438.

CBD 98

CBD THC Conditions Medicine 98

Cannabis Law Report

OCTOBER 26, 2021

MyMD plans to advance MYMD-1 in the clinic with two simultaneous Phase 2 trials beginning in the current quarter, one for delaying aging and prolonging healthy lifespan, and the second for COVID-19-associated depression and cytokine elevation. Dr. Chapman Bio. Chapman has operated Chapman Pharmaceutical Consulting, Inc., 646) 421-9523.

Pharmaceutical 40

Pharmaceutical Clinical Trials Research and Development Therapy 40

Cannabis Law Report

NOVEMBER 15, 2021

The Company is developing this product candidate as a prophylactic treatment against SARS and influenza and has engaged Syneos Health to assist with the optimal clinical trial design. FINANCIAL RESULTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2021 AND 2020. Three Months Ended September 30, 2021 and 2020.

Pharmaceutical 40

Pharmaceutical Research and Development Clinical Trials Chronic Pain 40

Cannabis Law Report

OCTOBER 12, 2021

SAN DIEGO–(BUSINESS WIRE)– #CBD — Radicle Science , a transformative healthtech B-corp validating consumer health products for the first time, secured its initial seed funding in Q4 2020 and surpassed numerous major milestones with accelerating momentum in the first three quarters of 2021. Notably, Peter H.

Clinical Trials 40

Clinical Trials Research and Development Sleep Cannabinoids 40

Cannabis Law Report

NOVEMBER 15, 2021

Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law. Investor Contact: Sanjay M.

Research and Development 40

Research and Development Therapy Clinical Trials Supply Chain 40

Cannabis Law Report

OCTOBER 12, 2021

FDA) or equivalent foreign regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final approval from the U.S. Food and Drug Administration (U.S. FDA or equivalent foreign regulatory agencies, the unknown outcome of any applications or requests to U.S.

Programs 40

Programs Clinical Trials Research and Development Therapy 40

Cannabis Law Report

FEBRUARY 9, 2022

These are the very first draft rules that we’re seeing, so it really is a kind of pivotal event.”. Oregonians voted to set up a system that would allow the use of psilocybin in some therapies back in 2020 by passing ballot Measure 109. Backstrom said the advisory board also recommended the OHA reevaluate its rules every year.

Clinical Trials 52

Clinical Trials Microdosing Safety Conditions 52

Cannabis Law Report

SEPTEMBER 20, 2021

Delic expects to open 15 additional clinics across the country over the coming 18 months, further expanding access to millions who can benefit from psychedelic treatment for a variety of mental health conditions. Transaction Highlights. Prior to this Transaction, KWC has grown without taking outside capital.

Treatment 52

Treatment Media Research and Development Patients 52

Cannabis Law Report

NOVEMBER 10, 2021

IND-enabling studies for Envelta are being performed under a Cooperative Research and Development Agreement (CRADA) with NCATS entered into by Virpax in August of 2020. “We The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Research and Development 40

Research and Development Chronic Pain Pharmaceutical Clinical Trials 40

Cannabis Law Report

SEPTEMBER 3, 2019

Sales generation from the facility is expected to begin in the first half of 2020, subject to receipt of certain local authorizations and a certification from the Therapeutic Goods Association of Australia. “We MediPharm Labs Australia received its cannabis manufacturing licence from the ODC under the Narcotics Drugs Act 1967 on May 21, 2019.

Pharmaceutical 45

Pharmaceutical Extraction Research and Development Supply Chain 45

Cannabis Law Report

JANUARY 18, 2019

Schedule of Events: Tuesday Jan 22nd 4-6:00 pm. Cannabis 2020 and beyond. CannaTech is the only Medical Cannabis event of its kind with a global focus that offers senior industry leaders, medical and scientific experts, and new ventures the platform to come together, drive innovation, form partnerships and promote knowledge exchange.

Research and Development 40

Research and Development Clinical Trials Extraction Therapy 40

Cannabis Law Report

NOVEMBER 7, 2019

Phase one of the ‘smart’ greenhouse development is scheduled to be in production by late 2020 and is projected to be the largest medicinal cannabis greenhouse project of its kind in Australia to date. Cannatrek is actively working on clinical trial protocols with a dedicated focus on mental health.

Medicine 40

Medicine Patients Research and Development Clinical Trials 40

Cannabis Law Report

DECEMBER 21, 2021

billion in 2020 (Grandview Research). billion (2020). billion during the same period in 2020. This service is available to businesses, K-12 schools, universities, event venues, medical offices, hospitality groups, and more to facilitate the safe return of people to in-person environments. from 2021 to 2028.

Research and Development 40

Research and Development Supply Chain Data Business 40

Healer

DECEMBER 17, 2021

Drug interactions reported in the scientific literature most often occur at very high doses used in clinical trials of epilepsy and other conditions.[1]. Adverse events reported for these participants were mild and included fatigue, diarrhea, and nausea. [7]. The Journal of Clinical Pharmacology 60.4 2020): 432-438. [6]

CBD 52

CBD THC Conditions Medicine 52

Cannabis Law Report

NOVEMBER 24, 2021

The Office of Drug Control (ODC) (ODC 2020 ), alongside the Therapeutic Goods Administration (TGA), regulates the production of cannabis and cannabis products. The outlier is ACT which in 2020 legalised cannabis for recreational use. 2020 ), stigmatisation (St Pierre et al. 2020 ; Balneaves et al. 2019 ; Sarris et al.

Research and Development 52

Research and Development Medicine Access Media 52

Veriheal

JULY 12, 2021

According to the American Psychiatric Association , PTSD is a “psychiatric disorder that may occur in people who have experienced or witnessed a traumatic event such as natural disaster, as a serious accident, a terrorist act, war/combat or rape or who have been threatened with death, sexual violence or serious injury”.

Treatment 105

Treatment Sleep Clinical Trials Data 105

CannaMD

MARCH 8, 2020

In January of 2020, the Journal of the American College of Cardiology published a review titled Marijuana Use in Patients With Cardiovascular Disease. Researchers summarized five key points from the 2020 review : * We estimate that more than 2 million U.S. Marijuana Heart Study Summary. a heart attack). More research is needed.

Patients 104

Patients Marijuana Research and Development Clinical Trials 104